Liposome-nucleic acid immunotherapeutics

Expert Opinion on Drug Delivery

Volumn 5, Issue 1, 2008, Pages 11-24

  Dow, Steven W ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Adjuvants; Innate immune; Interferons; Toll like receptors

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ALUMINUM HYDROXIDE; ANTIGEN; CANCER VACCINE; CD8 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; CYTOPLASMIC RECEPTOR; FREUND ADJUVANT; GAMMA INTERFERON; IMIDAZOLE DERIVATIVE; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; LIPOSOME; MPL; MURAMYL DIPEPTIDE; MURAMYL TRIPEPTIDE; NUCLEIC ACID; PATTERN RECOGNITION RECEPTOR; PHOSPHATIDYLETHANOLAMINE; PLASMID DNA; POLYINOSINIC POLYCYTIDYLIC ACID; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ANTIVIRAL ACTIVITY; ASTHMA; BASAL CELL CARCINOMA; BONE CANCER; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEGRADATION KINETICS; DENDRITIC CELL; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENDOSOME; HUMAN; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFLUENZA; INFLUENZA VIRUS; INNATE IMMUNITY; INTRACELLULAR TRANSPORT; LIPOSOMAL DELIVERY; LUNG METASTASIS; MACROPHAGE ACTIVATION; NATURAL KILLER CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; TUMOR IMMUNITY;

ANIMALS; HUMANS; IMMUNITY, NATURAL; IMMUNOTHERAPY; LIPOSOMES; NEOPLASMS; NUCLEIC ACIDS;

EID: 39049165612     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.5.1.11     Document Type: Review

References (116)

1. Heine H, Lien E. Toll-like receptors and their function in innate and adaptive immunity. Int Arch Allergy Immunol 2003;130:180-92
2. Janeway CA Jr, Medzhitov R. Innate immune recognition. Ann Rev Immunol 2002;20:197-216
3. Medzhitov R, Janeway CA Jr. Innate immune recognition and control of adaptive immune responses. Semin Immunol 1998;10:351-3
4. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007;13:552-9
5. Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol 2006;7:1266-73
6. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5:471-84
7. Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev 2007;7:31-40
8. Delbridge LM, O'Riordan MX. Innate recognition of intracellular bacteria. Curr Opin Immunol 2007;19:10-16
9. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. Nod-like proteins in immunity, inflammation and disease. Nat Immunol 2006;7:1250-7
10. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev 2004;4:499-511
11. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006;311:1-16
12. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-80
13. Lee HK, Iwasaki A. Innate control of adaptive immunity: dendritic cells and beyond. Semin Immunol 2007;19:48-55
14. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95
15. Strober W, Murray PJ, Kitani A, Watanabe T. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev 2006;6:9-20
16. Peyrin-Biroulet L, Vignal C, Dessein R, Simonet M, Desreumaux P, Chamaillard M. NODs in defence: from vulnerable antimicrobial peptides to chronic inflammation. Trends Microbiol 2006;14:432-8
17. Eckmann L, Karin M. NOD2 and Crohn's disease: loss or gain of function? Immunity 2005;22:661-7
18. Hsu YM, Zhang Y, You Y, et al. The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat Immunol 2007;8:198-205
19. Kobayashi KS, Eynon EE, Flavell RA. Intracellular debugging. Nat Immunol 2003;4:652-4
20. Chamaillard M, Hashimoto M, Horie Y, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 2003;4:702-7
21. Ishii KJ, Coban C, Kato H, et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 2006;7:40-8
22. Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006;441:101-5
23. Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004;5:730-7
24. Takaoka A, Wang Z, Choi MK, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007;448:501-5
25. Stetson DB, Medzhitov R. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 2006;24:93-103
26. Honda K, Ohba Y, Yanai H, et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005;434:1035-40
27. Ulevitch RJ. Therapeutics targeting the innate immune system. Nat Rev 2004;4:512-20
28. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007;117:1184-94
29. Ishii KJ, Gursel I, Gursel M, Klinman DM. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides. Curr Opin Mol Ther 2004;6:166-74
30. Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004;199:201-16
31. Kleinerman ES. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am 1995;9:927-38
32. Kleinerman ES, Maeda M, Jaffe N. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res 1993;62:101-7
33. Gianan MA, Kleinerman ES. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update. Cancer Biother Radiopharm 1998;13:363-8
34. MacEwen EG, Kurzman ID, Vail DM, et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999;5:4249-58
35. Vail DM, MacEwen EG, Kurzman ID, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res 1995;1:1165-70
36. Murray JL, Kleinerman ES, Cunningham JE, et al. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J Clin Oncol 1989;7:1915-25
37. Tanguay S, Bucana CD, Wilson MR, Fidler IJ, von Eschenbach AC, Killion JJ. In vivo modulation of macrophage tumoricidal activity by oral administration of the liposome-encapsulated macrophage activator CGP 19835A. Cancer Res 1994;54:5882-8
38. Liu Y, Liggitt D, Zhong W, Tu G, Gaensler K, Debs R. Cationic liposome-mediated intravenous gene delivery. J Biol Chem 1995;270:24864-70.
39. Liu Y, Mounkes LC, Liggitt HD, et al. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol 1997;15:167-73
40. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Potter TA. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 1999;163:1552-61
41. Whitmore M, Li S, Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther 1999;6:1867-75
42. Whitmore MM, Li S, Falo L Jr, Huang L. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol Immunother 2001;50:503-14
43. Lanuti M, Rudginsky S, Force SD, et al. Cationic lipid: bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Res 2000;60:2955-63
44. Wilson A, Pitt B, Li S. Complex roles of CpG in liposomal delivery of DNA and oligonucleotides. Biosci Rep 2002;22:309-22
45. Gursel I, Gursel M, Ishii KJ, Klinman DM. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 2001;167:3324-8
46. Khazanov E, Simberg D, Barenholz Y. Lipoplexes prepared from cationic liposomes and mammalian DNA induce CpG-independent, direct cytotoxic effects in cell cultures and in mice. J Gene Med 2006;8:998-1007
47. Zaks K, Jordan M, Guth A, et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 2006;176:7335-45
48. Wong JP, Yang H, Nagata L, et al. Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. Vaccine 1999;17:1788-95
49. Sakurai F, Terada T, Maruyama M, et al. Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-beta gene and poly I: poly C in a murine lung metastasis model. Cancer Gene Ther 2003;10:661-8
50. Hamm S, Heit A, Koffler M, et al. Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivo. Int Immunol 2007;19:297-304
51. Sellins K, Fradkin L, Liggitt D, Dow S. Type I interferons potently suppress gene expression following gene delivery using liposome(-)DNA complexes. Mol Ther 2005;12:451-9
52. Gowen BB, Fairman J, Smee DF, et al. Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antiviral Res 2006;69:165-72
53. Moss EG, Taylor JM. Small-interfering RNAs in the radar of the interferon system. Nat Cell Biol 2003;5:771-2
54. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5:834-9
55. de Veer MJ, Sledz CA, Williams BR. Detection of foreign RNA: implications for RNAi. Immunol Cell Biol 2005;83:224-8
56. Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 2006;58:32-45
57. Zhou X, Huang L. DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. Biochim Biophys Acta 1994;1189:195-203
58. Wrobel I, Collins D. Fusion of cationic liposomes with mammalian cells occurs after endocytosis. Biochim Biophys Acta 1995;1235:296-304
59. Zuhorn IS, Kalicharan R, Hoekstra D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis. J Biol Chem 2002;277:18021-8
60. Takeuchi O, Akira S. Signaling pathways activated by microorganisms. Curr Opin Cell Biol 2007;19:185-91
61. Zelphati O, Szoka FC Jr. Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA 1996;93:11493-8
62. Guiducci C, Ott G, Chan JH, et al. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med 2006;203:1999-2008
63. Honda K, Yanai H, Negishi H, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005;434:772-7
64. Cui Z, Han SJ, Vangasseri DP, Huang L. Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol Pharm 2005;2:22-8
65. Niven R, Pearlman R, Wedeking T, et al. Biodistribution of radiolabeled lipid-DNA complexes and DNA in mice. J Pharm Sci 1998;87:1292-9
66. Ishiwata H, Suzuki N, Ando S, Kikuchi H, Kitagawa T. Characteristics and biodistribution of cationic liposomes and their DNA complexes. J Control Rel 2000;69:139-48
67. Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model. Cancer Biol Ther 2004;3:197-204
68. Delepine P, Guillaume C, Montier T, et al. Biodistribution study of phosphonolipids: a class of non-viral vectors efficient in mice lung-directed gene transfer. J Gene Med 2003;5:600-8
69. Tranchant I, Thompson B, Nicolazzi C, Mignet N, Scherman D. Physicochemical optimisation of plasmid delivery by cationic lipids. J Gene Med 2004;6(Suppl 1):S24-S35
70. Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 2007;4:289-94
71. CpG 7909: PF 3512676, PF-3512676. Drugs R D 2006;7:312-16
72. Dow SW, Elmslie RE, Fradkin LG, et al. Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases. Hum Gene Ther 1999;10:2961-72
73. Egeter O, Mocikat R, Ghoreschi K, Dieckmann A, Rocken M. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res 2000;60:1515-20
74. McLachlan G, Stevenson BJ, Davidson DJ, Porteous DJ. Bacterial DNA is implicated in the inflammatory response to delivery of DNA/DOTAP to mouse lungs. Gene Ther 2000;7:384-92
75. Blezinger P, Freimark BD, Matar M, et al. Intratracheal administration of interleukin 12 plasmid-cationic lipid complexes inhibits murine lung metastases. Hum Gene Ther 1999;10:723-31
76. Chesnoy S, Huang L. Structure and function of lipid-DNA complexes for gene delivery. Ann Rev Biophys Biomol Struct 2000;29:27-47
77. Liu F, Shollenberger LM, Huang L. Non-immunostimulatory nonviral vectors. FASEB J 2004;18:1779-81
78. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002;9:1647-52
79. Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 2000;18:781-92
80. Khanna C, Lindblad-Toh K, Vail D, et al. The dog as a cancer model. Nat Biotechnol 2006;24:1065-66
81. Dow S, Elmslie R, Kurzman I, MacEwen G, Pericle F, Liggitt D. Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum Gene Ther 2005;16:937-46
82. Kamstock D, Guth A, Elmslie R, et al. Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Ther 2005
83. Veir JK, Lappin MR, Dow SW. Evaluation of a novel mmunotherapy for treatment of chronic rhinitis in cats. J Feline Med Surg 2006;8:400-11
84. Johnson LR, Maggs DJ. Feline herpesvirus type-1 transcription is associated with increased nasal cytokine gene transcription in cats. Vet Microbiol 2005;108:225-33
85. Allison AC, Byars NE. Adjuvant formulations and their mode of action. Semin Immunol 1990;2:369-74
86. Cui Z, Huang L. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother 2005;54:1180-90
87. Chikh GG, Kong S, Bally MB, Meunier JC, Schutze-Redelmeier MP. Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J Immunol 2001;167:6462-70
88. Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier MP. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 2003;21:3319-29
89. Gursel M, Tunca S, Ozkan M, Ozcengiz G, Alaeddinoglu G. Immunoadjuvant action of plasmid DNA in liposomes. Vaccine 1999;17:1376-83
90. Latif N, Bachhawat BK. The effect of surface charges of liposomes in immunopotentiation. Biosci Rep 1984;4:99-107
91. Latif NA, Bachhawat BK. The effect of surface-coupled antigen of liposomes in immunopotentiation, Immunol Lett 1987;15:45-51
92. Rejman J, Bragonzi A, Conese M. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol Ther 2005;12:468-74
93. Zuhorn IS, Hoekstra D. On the mechanism of cationic amphiphile-mediated transfection. To fuse or not to fuse: is that the question? J Membr Biol 2002;189:167-79
94. Perrie Y, McNeil S, Vangala A. Liposome-mediated DNA immunisation via the subcutaneous route. J Drug Target 2003;11:555-63
95. Perrie Y, Frederik PM, Gregoriadis G. Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine 2001;19:3301-10
96. Nakanishi T, Kunisawa J, Hayashi A, et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins. Biochem Biophys Res Commun 1997;240:793-97
97. Vangasseri DP, Cui Z, Chen W, Hokey DA, Falo LD Jr, Huang L. Immunostimulation of dendritic cells by cationic liposomes. Mol Membrane Biol 2006;23:385-95
98. Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 2004;22:1903-13
99. Korsholm KS, Agger EM, Foged C, et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 2007;121:216-26
100. Guy B, Pascal N, Francon A, et al. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine 2001;19:1794-805
101. Hattori Y, Kawakami S, Suzuki S, Yamashita F, Hashida M. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Biochem Biophys Res Commun 2004;317:992-9
102. Simberg D, Weisman S, Talmon Y, Barenholz Y. DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst 2004;21:257-317
103. Conry RM, Curiel DT, Strong TV, et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 2002;8:2782-7
104. Shi Y, Zheng W, Rock KL. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci USA 2000;97:14590-5
105. Nakanishi T, Hayashi A, Kunisawa J, et al. Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. Eur J Immunol 2000;30:1740-7
106. Walker C, Selby M, Erickson A, Cataldo D, Valensi JP, Van Nest GV. Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway. Proc Natl Acad Sci USA 1992;89:7915-18
107. Daubenberger CA. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines. Curr Opin Mol Ther 2007;9:45-52
108. McCluskie MJ, Krieg AM. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol 2006;311:155-78
109. Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides, Int Rev Immunol 2006;25:135-54
110. Kensil CR, Mo AX, Truneh A. Current vaccine adjuvants: an overview of a diverse class. Front Biosci 2004;9:2972-88
111. Dalpke A, Zimmermann S, Heeg K. Immunopharmacology of CpG DNA. Biol Chem 2002;383:1491-500
112. Jiao X, Wang RY, Qiu Q, Alter HJ, Shih JW. Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J Gen Virol 2004;85:1545-53
113. Salem ML, El-Naggar SA, Kadima A, Gillanders WE, Cole DJ. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine 2006;24:5119-32
114. Fujimura T, Nakagawa S, Ohtani T, Ito Y, Aiba S. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. Eur J Immunol 2006;36:3371-80
115. Molina MC, Armstrong TK, Zhang Y, Patel MM, Lentz YK, Anchordoquy TJ. The stability of lyophilized lipid/DNA complexes during prolonged storage. J Pharm Sci 2004;93:2259-73
116. Anchordoquy TJ, Allison SD, Molina MC, Girouard LG, Carson TK. Physical stabilization of DNA-based therapeutics. Drug Discov Today 2001;6:463-70